RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Science Advances · 2023
DOI: 10.1126/sciadv.adg3193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Mikito Shimizu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Clinical Research, National Hospital Organization Osaka-Minami Medical Center, Kawachinagano, Osaka, Japan.
- Department of Neurotherapeutics, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Neurology, Higashiosaka City Medical Center, Higashiosaka, Osaka, Japan.
- Graduate School of Data Science, Shiga University, Hikone, Shiga, Japan.
- Department of Health Sciences, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
ORCID-Profile: Mikito Shimizu, Naoyuki Shiraishi, Satoru Tada, Tsutomu Sasaki, Goichi Beck, Hisae Sumi, Yoko Ishida, Toru Koda, Minami Kanakura, Tsuneo Nakajima, Masanori P Takahashi, Toshihide Yamashita, Tatsusada Okuno
Zitieren
APA
Shimizu, M., Shiraishi, N., Tada, S., Sasaki, T., Beck, G., Nagano, S., Kinoshita, M., Sumi, H., Sugimoto, T., Ishida, Y., Koda, T., Ishikura, T., Sugiyama, Y., Kihara, K., Kanakura, M., Nakajima, T., Takeda, S., Takahashi, M. P., Yamashita, T., …, & Mochizuki, H. (2023). RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS. Science Advances. https://doi.org/10.1126/sciadv.adg3193
Vancouver
Shimizu M, Shiraishi N, Tada S, Sasaki T, Beck G, Nagano S, et al. RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS. Science Advances. 2023. doi:10.1126/sciadv.adg3193
BibTeX
@article{Shimizu2023,
author = {Shimizu, Mikito and Shiraishi, Naoyuki and Tada, Satoru and Sasaki, Tsutomu and Beck, Goichi and Nagano, Seiichi and Kinoshita, Makoto and Sumi, Hisae and Sugimoto, Tomoyuki and Ishida, Yoko and Koda, Toru and Ishikura, Teruyuki and Sugiyama, Yasuko and Kihara, Keigo and Kanakura, Minami and Nakajima, Tsuneo and Takeda, Shuko and Takahashi, Masanori P and Yamashita, Toshihide and Okuno, Tatsusada and Mochizuki, Hideki},
title = {RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.adg3193}
}
EUVIMED